Cytotoxic Drugs Market: Rising Prevalence of Cancer Cases Coupled with Higher Access to Cancer Care in Emerging Markets Expected to Fuel Revenue Growth: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Cytotoxic Drugs Market: Rising Prevalence of Cancer Cases Coupled with Higher Access to Cancer Care in Emerging Markets Expected to Fuel Revenue Growth: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Introduction

Cytotoxic drugs are being used as a potent drug in cancer treatment. Cytotoxic drugs are also used in developing ADCs (antibody-drug conjugates): There are two types of cytotoxic agents available currently, one is DNA modifying agents and the other is microtubule disrupting agents which effects the cell cycle in order restrict them to multiply and unlike drugs of category which are cell life cycle specific, DNA modifying agents kill cells at any point.

Cytotoxic Drugs included in the report are products that are used for cancer treatment and research. The growth of the global Cytotoxic Drugs market is primarily driven by increasing prevalence of cancer indications, rising population prescribed with chemotherapy, awareness programs conducted by public and private associations, and other socio-economic factors. In terms of revenue, cytotoxic drugs segmented as antimetabolites are estimated dominated the global market in drug type category with over two third revenue share in recent years. 

Generic Cytotoxic Drugs industry is more accessible to new players given fragmented nature of the cytotoxic drug market in emerging economies. Generic version of cytotoxic drugs are more affordable and easily available among patient population in low income settings. Physicians in developed market however are opting for branded Cytotoxic Drugs due to positive outcomes in commercial usage. This boosts revenue generation for the leading manufacturers of branded cytotoxic drugs. Stringent regulations observed globally for cytotoxic drugs is a factor expected to hamper the revenue growth of the global Cytotoxic Drugs market over the forecast period.   

 

In the drug type category for cytotoxic drugs, antimetabolites is the leading segment with most of the market share by value and volume. Others section is leading due to the inclusion of many types like metal salts, topoisomerase ii inhibitors, enzyme and more.

The global Cytotoxic Drugs market is estimated to expand at a CAGR of 0.9% over the forecast period of 2018 – 2028 to reach value of over US$ 17 Bn at the end of 2028. A significant drawback of the cytotoxic drugs market is manufacturers not filing for regulatory approval; delays or denials of approval; or, manufacturers awaiting the results of reimbursement negotiations prior to launching the drug in the country, etc. These factors cumulatively contribute towards cytotoxic drugs not being available in most of the countries or suffering critical shortage. Less than 20% of the entire gamut of cytotoxic drugs are available in most of the pharma emerging markets.

Geographically, the global Cytotoxic Drugs market is segmented into eight major regions, namely North America, Latin America, Western Europe, Eastern Europe, Asia Pacific (Asia-Pacific excluding China & Japan), China, Japan and Middle East & Africa (MEA). In terms of value, North America is expected to be the dominant regional market for Cytotoxic Drugs by 2018 end and is expected to expand at a healthy CAGR over the forecast period. Asia Pacific excluding China and Japan is expected to witness significant growth in the global Cytotoxic Drugs market over the forecast period.

Europe is expected to grow in the global Cytotoxic Drugs market due to increasing demand for premium-priced products and favorable conditions for cancer care. Also, increasing number of specialty programs will lead to increased access to cytotoxic drugs. APECJ cytotoxic drugs market is estimated to reflect impressive growth due to expanding patient volume and price cutting. 

Examples of some of the key players operating in the Cytotoxic Drugs market include Sanofi, Pfizer, Novartis AG, Johnson and Johnson, F. Hoffmann-La Roche AG, Lonza, Celgene Corp., Amgen Inc. , GlaxoSmithKline PLC, Merck & Co., Inc., Eli Lilly and Company and Teva Pharmaceutical.

Key Segments

The report analyses the global Cytotoxic Drugs market based on the regions and presents the forecast in terms of value for the next 10 years. The regions covered in the report include:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APECJ
  • Japan
  • China
  • Middle East & Africa

The report analyses the global Cytotoxic Drugs market based on the product type and presents the forecast in terms of value for the next 10 years. The product types covered in the report include: 

  • Branded Drugs
  • Generic Drugs

The report analyses the global Cytotoxic Drugs market based on the drug type segment and presents the forecast in terms of value for the next 10 years. The drug type covered in the report include:  

  • Alkylating Agents
  • Antitumor Antibiotics 
  • Antimetabolites
  • Plant Alkaloids
  • Others

The report analyses the global Cytotoxic Drugs market based on the Route of Administration segment and presents the forecast in terms of value for the next 10 years. The Route of Administration covered in the report include:  

  • Oral
  • Parenteral

The report analyses the global Cytotoxic Drugs market based on the End User segment and presents the forecast in terms of value for the next 10 years. The End User covered in the report include:  

  • Hospital
  • Cancer Research Center
  • Drug Testing Laboratory
  • CDMOs

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Cytotoxic Drugs Market